Page 234 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
mutations. In this context, based on the MC morphology and the expression of CD30 on MC, a WDSM should be consid- ered. In addition, we confirmed a previous report regarding the association between the absence of CD2 expression in Adv-SM compared with ISM patients. This observation could be explained by the previous study reporting that the lack of CD2 may be associated with the loss of CD2- CD58 interaction.14 This could lead to the absence of ho- motypic aggregation, resulting in the spreading of SM into extramedullary organs. We also provided further findings on the association between the lack of CD2 expression on BMMC, adverse additional mutations, and poor outcomes. In addition to the potential increased risk of spreading of CD2- tumoral MC, this finding might be explained by lower platelet levels and a tendency towards a higher frequency of KIT D816V-negative status among CD2- patients, who have been associated with a poor prognosis.15 Besides the potential interest from a pathophysiological perspective, the poor prognostic significance of the lack of CD2 may serve as a cost-effective tool for identifying high-risk Adv- SM patients, especially when next-generation sequencing (and thus the MARS score) is not available. Further studies are required to determine whether this prognostic impact is present in patients treated with avapritinib.
Authors
Julien Rossignol,1 Sophie Georgin-Lavialle,2 Danielle Canioni,3 Omer Beganovic,4,5 Chantal Brouzes,4,5 Olivier Fain,6 Maël Heiblig,7 Clément Gourguechon,8 Philippe Guilpain,9 Cristina Bulai-Livideanu,10 Stéphane Barete,11 Julie Agopian,12 Fabienne Brenet,12 Patrice Dubreuil,12 Richard Lemal,13 Olivier Tournilhac,13 Louis Terriou,14 David Launay,14,15 Laurence Bouillet,16 Catharina Chatain,16 Ghandi Damaj,17 Thomas Ballul,1 Celine Greco,18 Laura Polivka,1,19 Laurent Frenzel,1 Cécile Meni,1 Hassiba Bouktit,1 Dina Benabou,1 Clotilde Devin,1 Caroline Gaudy-Marqueste,20 Marie Gousseff,21 Edwige Le Mouel,22 Antoine Neel,23 Dana Ranta,24 Roland Jaussaud,25 Thierry Jo Molina,3 Julie Bruneau,3 Rose-Marie Javier,26 Fabien Pelletier,27 Florence Castelain,27 Frederique Retornaz,28 Quentin Cabrera,29 Patricia Zunic,29 Marie Pierre Gourin,30 Ewa Wierzbicka-Hainaut,31 Jean François Viallard,32 Christian Lavigne,33 Cyrille Hoarau,34 Isabelle Durieu,35 Sophie Dimicoli-Salazar,36 Jose Miguel Torregrosa-Diaz,37 Audrey Duval,38 Nicolas Garcelon,38 Jeremie Lespinasse,39 Angèle Soria,40 Yannick Chantran,41 Michel Arock,42 Christine Bodemer,1,19 Olivier Lortholary,1 Vahid Asnafi,4,5 Olivier Hermine1 and Ludovic Lhermitte4,5
1CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker- Children’s Hospital, Paris Centre University, Paris; 2Department of Internal Medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris; 3CEREMAST, Department of Pathology, Necker-Children’s Hospital, AP-HP, Paris Centre University, Paris; 4Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris; 5Hôpital
Necker Enfants-Malades, Laboratoire d’Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris; 6Department of Internal Medicine, Sorbonne University, Saint-Antoine Hospital, AP-HP, Paris; 7CEREMAST, Department of Hematology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite; 8Department of Hematology, Amiens University Hospital, Amiens; 9CEREMAST, Department of Internal Medicine-Multi-organ Diseases, Saint-Eloi University Hospital, Montpellier University, Montpellier; 10CEREMAST, Department of Dermatology, Hôpital Larrey, CHU Toulouse, Toulouse; 11CEREMAST, Dermatology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris; 12Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille; 13CEREMAST, Adult Clinical Hematology, CHU Clermont-Ferrand, INSERM CIC501, EA 7453 - Clermont Auvergne University, Clermont-Ferrand; 14CEREMAST, Department of Internal Medicine and Clinical Immunology, Claude Huriez, CHRU Lille, Lille; 15Lille University, INSERM U995 LIRIC, CHU Lille, and Referral Center for Rare Systemic Autoimmune Diseases North and North-West of France, Lille; 16CEREMAST, Clinical Immunology / Internal Medicine Department, National Reference Center for Angioedema, Grenoble University Hospital, Grenoble; 17CEREMAST, Hematology Institute, Normandy University School of Medicine, Caen; 18CEREMAST, Department of Pain and Palliative Care Unit, Necker-Children’s Hospital, AP-HP, Paris Centre University, Paris; 19Department of Dermatology, Reference Center for Genodermatoses (MAGEC), AP-HP, Necker-Children’s Hospital, Paris Centre University, Paris; 20CEREMAST, Department of Dermatology, Aix-Marseille University, CHU Timone, Marseille; 21Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique, Vannes; 22CEREMAST, Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes; 23CEREMAST, Department of Internal Medicine, Hôtel-Dieu University Hospital, Nantes; 24Department of Hematology, Nancy University Hospital, Nancy; 25Department of Internal Medicine and Clinical Immunology, Vandoeuvre-lès-Nancy; 26CEREMAST, Department of Rheumatology, Strasbourg University Hospital, Strasbourg; 27CEREMAST, Department of Dermatology, Allergology Unit, University Hospital of Besançon, Besançon; 28Unité de Soins et de Recherche en Médecine Interne et Maladies Infectieuses, European Hospital, Marseille; 29Department of Hematology, Sud Reunion University Hospital, Saint Pierre, La Réunion; 30CEREMAST, Department of Hematology, CHU Dupuytren, Limoges; 31CEREMAST, Department of Dermatology, CHU de Poitiers, Poitiers; 32Department of Internal Medicine and Infectious Diseases, Haut-Lévêque Hospital, CHRU Bordeaux, Bordeaux University, Bordeaux; 33CEREMAST, Department of Internal Medicine and Clinical Immunology, University Hospital, Angers; 34CEREMAST, Department of Clinical Immunology and Allergology, CHRU Tours, Tours; 35CEREMAST, Department of Internal Medicine, Adult Cystic Fibrosis Care Center, Hospices Civils de Lyon, Lyon; 36Department of Hematology, CHU Bordeaux, Bordeaux; 37Department of Hematology, CHU Poitiers, Poitiers; 38Paris Centre University, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris; 39eXYSTAT, Malakoff, Paris; 40CEREMAST, Department of Dermatology and Allergy, Tenon Hospital, Sorbonne University, Paris; 41CEREMAST, Department of Biological Immunology, Saint-Antoine Hospital, Sorbonne University, Paris and 42CEREMAST,
Haematologica | 110 January 2025
226